3,495 Shares in Stryker Corporation $SYK Bought by Bluebird Wealth Management LLC

Key Points

• Bluebird Wealth Management established a new position of 3,495 Stryker shares in Q4, valued at about $1.228 million.
• Stryker missed the quarter—EPS $2.60 vs. $2.98 expected and revenue $6.02B vs. $6.34B—while issuing FY2026 guidance of EPS 14.90–15.10.
• Analysts show a consensus "Moderate Buy" (16 Buys, 6 Holds) with an average target price of $395.48, though several firms recently trimmed targets.

Bluebird Wealth Management LLC bought a new position in shares of Stryker Corporation (NYSE:SYK - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,495 shares of the medical technology company's stock, valued at approximately $1,228,000.

Other institutional investors have also recently made changes to their positions in the company. Sequoia Financial Advisors LLC grew its position in Stryker by 7.4% during the fourth quarter. Sequoia Financial Advisors LLC now owns 13,997 shares of the medical technology company's stock valued at $4,920,000 after buying an additional 966 shares during the period. Alecta Tjanstepension Omsesidigt grew its position in Stryker by 6.4% during the fourth quarter. Alecta Tjanstepension Omsesidigt now owns 487,500 shares of the medical technology company's stock valued at $171,317,000 after buying an additional 29,200 shares during the period. Ballast Advisors LLC grew its position in Stryker by 1.8% during the fourth quarter. Ballast Advisors LLC now owns 4,081 shares of the medical technology company's stock valued at $1,434,000 after buying an additional 71 shares during the period. Swedbank AB grew its position in Stryker by 6.6% during the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company's stock valued at $45,349,000 after buying an additional 7,934 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Stryker by 3.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 723,705 shares of the medical technology company's stock valued at $251,980,000 after buying an additional 24,421 shares during the period. Hedge funds and other institutional investors own 77.09% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. William Blair restated an "outperform" rating on shares of Stryker in a research report on Thursday, March 5th. Needham & Company LLC dropped their price target on shares of Stryker from $454.00 to $418.00 and set a "buy" rating on the stock in a research report on Friday, May 1st. Piper Sandler restated an "overweight" rating on shares of Stryker in a research report on Tuesday, January 27th. UBS Group dropped their price target on shares of Stryker from $400.00 to $380.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 17th. Finally, Wells Fargo & Company dropped their price target on shares of Stryker from $456.00 to $418.00 and set an "overweight" rating on the stock in a research report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $395.48.

Stryker Stock Down 1.1%

Shares of NYSE SYK opened at $292.13 on Thursday. The company's 50-day simple moving average is $342.12 and its 200-day simple moving average is $355.73. Stryker Corporation has a 52-week low of $289.91 and a 52-week high of $404.87. The firm has a market cap of $111.88 billion, a price-to-earnings ratio of 33.81, a price-to-earnings-growth ratio of 1.86 and a beta of 0.80. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the business earned $2.84 EPS. The firm's revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts predict that Stryker Corporation will post 14.97 EPS for the current fiscal year.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.